Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
- 1 November 1993
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 11 (11) , 2101-2111
- https://doi.org/10.1200/jco.1993.11.11.2101
Abstract
PURPOSEWe assessed the feasibility of noninvasive metabolic monitoring of cancer chemohormonotherapy using sequential quantitative positron emission tomographic (PET) scans of tumor glucose metabolism with the glucose analog 2-[18F]-fluoro-2-deoxy-D-glucose (FDG).PATIENTS AND METHODSEleven women with newly diagnosed primary breast cancers larger than 3 cm in diameter beginning a chemohormonotherapy program underwent a baseline and four follow-up quantitative PET scans during the first three cycles of treatment (days 0 to 63). Tumor response was sequentially determined clinically, radiographically, and then pathologically after nine treatment cycles.RESULTSEight patients had partial or complete pathologic responses. Their maximal tumor uptake of FDG assessed by PET decreased promptly with treatment to the following: day 8, 78 +/- 9.2% (P < .03); day 21, 68.1 +/- 7.5% (P < .025); day 42, 60 +/- 5.1% (P < .001); day 63, 52.4 +/- 4.4% (P < .0001) of the basal values. Tumor diameter did not decrease significan...Keywords
This publication has 0 references indexed in Scilit: